NICE Endorses Obecabtagene Autoleucel Therapy f...

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-dev...
Accelerating Access to Latin America Innovative Therapies Through Collaborati...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Weight Loss: Advances in Hormone-Based Obesity Treatments
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
AI in South African Healthcare: Professionals’ Confidence in Reducing A...
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health